Background: Anaemia is a serious complication of Crohn's disease that triggers hospitalization and, if not interfered with, may lead to death. Aims: To systematically summarize and compare the literature on anaemia in Crohn's disease. Methods: For this systematic review the literature was searched for English-language articles using anaemia, Crohn* and IBD as key words. 144 articles were identified and sorted according to the following topics: prevalence, aetiology, diagnostic tests and therapy. Results: The reported prevalence of anaemia varied between 6.2% and 73.7%, with higher reported frequencies in older studies and in in-patients. Iron deficiency is the most common underlying condition. Vitamin B12 deficiency is related to the extent of ileal resection but has rarely impact on anaemia. Diagnostic criteria are not established and treatment guidelines are missing. Oral iron supplementation seems effective for short periods but intolerance leads to discontinuation in up to 21%. Eleven of 11 studies show that oral iron enhances intestinal inflammation and colon carcinogenesis in animal models of colitis. Intravenous iron supplementation with iron sucrose has been tested in over 250 Crohn's disease patients, is safe, effective and does not carry such hazards. Conclusions: As disease activity is determining the degree of anaemia in Crohn's disease, implementation of more effective therapy for Crohn's disease will lower its incidence. However, further studies regarding the safety and effectiveness of iron supplementation are needed. © 2006 The Authors.

Introducción: La anemia falciforme es una hemoglobinopatía estructural de origen genético, se caracteriza por la presencia de hemoglobina falciforme. La hemoglobina anormal es inestable, tiende a polimerizarse y puede ocluir la microcirculación, produciendo manifestaciones multisistémicas tanto agudas como crónicas relacionándose con mayor riesgo de contraer infecciones. Objetivo: Describir la información del tema expuesto resaltando los aspectos más relevantes como diagnóstico y tratamiento. Metodología: Se efectuó una revisión bibliográfica con búsqueda electrónica en las siguientes bases de datos: PubMed, MEDLINE, Medscape, Scopus; y se incluyó diferentes tipos de artículo (artículos originales, revisiones de temas y guías de manejo) que abordaran la anemia de células falciformes en pediatría. Resultados: Se obtuvo una revisión de 22 artículos, donde se describe el tema de anemia de células falciformes, pautas y tratamientos basados en el manejo y control de los síntomas; se evidencia que el uso de ecografía doppler transcraneal y las transfusiones demostraron ser estrategias preventivas o de tratamiento eficaces para las complicaciones relacionadas con esta patología en los niños. Conclusiones: En Colombia, la prevalencia de la patología no se encuentra establecida. Por otra parte, las principales manifestaciones se relacionan con complicaciones de vaso-oclusión en los diferentes órganos y la asplenia funcional, la cual predispone a cuadros infecciosos

Resumen Objetivo: Analizar los estudios económicos completos con enfoque en tratamientos para la anemia falciforme Métodos: Estudio de revisión integradora de la literatura desarrollado mediante la recolección de datos en las bases electrónicas National Library of Medicine - Medline vía PubMed; Elservier's Scopus; Current Index to Nursing and Allied Health Literature; Science Direct y Web of Science con descriptores indexados en Medical Subject Headings. Los estudios fueron seleccionados mediante la prueba de relevancia y analizados de acuerdo con la clasificación de análisis económicos en salud y con el sistema de clasificación de la calidad de las evidencias y la fuerza de las recomendaciones. Resultados: Nueve artículos formaron parte de esta revisión, de los cuales siete fueron encontrados en la base Elservier's Scopus y dos en Medline vía PubMed. Todos son estudios completos con enfoque en las perspectivas del uso de hidroxiurea y transfusión sanguínea para el tratamiento de anemia falciforme. Conclusión: No se identificaron estudios realizados en Brasil con este tipo de análisis de anemia falciforme. Hay mucho por hacer a nivel mundial para evaluar las tecnologías vigentes, revaluar las que se utilizan en la actualidad e implementar el diagnóstico y tratamiento continuo, con un sistema que garantice una red de atención activa y eficiente para los pacientes.

Se reporta el caso de un hombre de 31 años de edad con diagnóstico de Leptospirosis y anemia hemolítica autoinmune con Coombs directo negativo que recibió como parte de su tratamiento penicilina intravenosa y esteroides, al cabo de 13 días se positivisa el coombs directo, se realiza estudio inmunohematológico y en el eluido los glóbulos rojos del paciente y se demuestra que reaccionan con eritrocitos sensibilizados con penicilina y no hemaglutina células sin sensibilizar

Este artículo no tiene resumen

Untreated preoperative anemia and acute perioperative blood loss may add to surgical risk. To understand the prevalence of anemia in surgical patients (with a primary focus on preoperative anemia), and the impact that preexisting anemia has on transfusion rates as well as on clinical and functional outcomes, a systematic review was performed of articles published between January 1966 and February 2003. The estimates of anemia prevalence in the literature ranged widely, from 5% in geriatric women with hip fracture to 75.8% in patients with Dukes stage D colon cancer. Diagnosis of anemia was most strongly associated with an increased risk of receiving an allogeneic transfusion. In general, patients who donated autologous blood preoperatively received less allogeneic blood than those who did not donate. There was some suggestion that lower hemoglobin levels are associated with decreased survival rates, although this was not found universally. Too few studies were found that evaluated the impact of anemia on other outcomes, such as functional status and costs and resource utilization, to draw reliable conclusions. Several other factors also limited the interpretation of the data, including the lack of a uniform definition for anemia and a dearth of studies expressly designed to quantify the prevalence and impact of anemia. Establishing a uniform definition and specifically evaluating the effect of anemia on outcomes are important considerations for future study.

OBJECTIVE:

To review the literature regarding current strategies for the management of anemia associated with treatment for chronic viral hepatitis C (HCV) in adults.

DATA SOURCES:

The MEDLINE/PubMed, EMBASE, and Cochrane databases were searched (January 1980-October 2012) for articles in English using the search terms anemia, ribavirin, dose reduction, erythropoietin stimulating agents, hepatitis C, HIV, liver transplant, telaprevir, and boceprevir.

STUDY SELECTION AND DATA EXTRACTION:

All relevant original studies, meta-analyses, systematic reviews, guidelines, and review articles were assessed for inclusion. References from pertinent articles were examined for additional content not found during the initial search.

DATA SYNTHESIS:

Standard of care for patients infected with HCV genotype 1 now requires a triple therapy regimen including an HCV NS3 protease inhibitor. These regimens lead to significantly higher rates of anemia compared to prior dual therapy regimens. Development of an optimal management strategy should begin with risk stratification. Ribavirin dose reductions have been recommended in the package inserts for the pegylated interferon products and studies have demonstrated the need for maintenance of 80% of the initial ribavirin dose to achieve optimal sustained virologic response (SVR) with dual therapy. The use of erythropoietin-stimulating agents has been shown to be effective for anemia caused by peginterferon and ribavirin without compromising SVR rates. Limited data have been published regarding the management of anemia with triple therapy; however, efficacy studies for boceprevir and telaprevir have used ribavirin dose reduction and erythropoietin-stimulating agents to successfully manage anemia.

CONCLUSIONS:

Anemia is a common adverse event associated with the use of ribavirin, and, more recently, the new HCV protease inhibitors. Ribavirin dose reduction should continue to be used as an initial anemia management strategy, with the use of erythropoietin alfa 40,000 units once weekly reserved for patients whose hemoglobin does not adequately respond to initial management strategies.

We hypothesized that chart reminders would decrease the number of cases in which a low admission hemoglobin level was missed or ignored. Additionally, we compared the cost of generating the chart reminders by hand with the estimated cost of modifying the university hospital information system for this function. For three months, two medical students reviewed all abnormal hemoglobin results and assigned those more than 1 g below normal limits to a control or study group. A questionnaire, placed in all study group charts, requested an explanation for the low hemoglobin level. Eleven of 141 study cases and 16 of 150 control cases failed the audit criteria (differences not significant). The cost was $308 compared with $3,000 for altering the hospital information system. We conclude that chart reminders did not improve the detection of anemia and that it cost less to test this intervention by manually simulating the computer function.

Este artículo no tiene resumen

Many patients with pernicious anemia are treated with lifelong intramuscular (IM) vitamin B12 replacement. As early as the 1950s, there were studies suggesting that oral vitamin B12 replacement may provide adequate absorption. Nevertheless, oral vitamin B12 replacement in patients with pernicious anemia remains uncommon in clinical practice. The objective of this review is to provide an update on the effectiveness of oral vitamin B12 for the treatment of pernicious anemia, the recommended dosage, and the required frequency of laboratory test and clinical monitoring. Relevant articles were identified by PubMed search from January 1, 1980 to March 31, 2016 and through hand search of relevant reference articles. Two randomized controlled trials, three prospective papers, one systematic review, and three clinical reviews fulfilled our inclusion criteria. We found that oral vitamin B12 replacement at 1000 μg daily was adequate to replace vitamin B12 levels in patients with pernicious anemia. We conclude that oral vitamin B12 is an effective alternative to vitamin B12 IM injections. Patients should be offered this alternative after an informed discussion on the advantages and disadvantages of both treatment options.